Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Date:2/21/2012

dit agreement is appropriate to provide additional information to investors to demonstrate the company's ability to comply with financial debt covenants (which are calculated using a measure similar to adjusted EBITDA) and assess the company's ability to incur additional indebtedness. Whenever Mylan uses such a non-GAAP measure, it will provide a reconciliation of non-GAAP financial measures to the most closely applicable GAAP financial measure. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS to adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS for the three-months and years ended December 31, 2011 and 2010 (in millions, except per share amounts): Three months ended December 31,Year ended December 31,2011201020112010GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS

$129.5

$0.30$
2.6

$0.01$536.8

$1.22$223.6

$0.68Purchase accounting related amortization (included in cost of sales) (a)

86.891.6364.8309.2Litigation settlements, net

20.1112.848.6127.1Interest expense, primarily amortization of convertible debt discount

13.018.049.860.0Financing related costs (included in other (expense) income, net)

34.022.434.037.4Restructuring & other special items included in:Cost of sales

0.82.88.46.7Research and development expense

0.64.93.69.9Selling, general and administrative expense

8.120.044.963.5Other (expense) income, net

1.4(8.8)0.21.1Tax effect of the above items and other income tax related items

(67.7)(8
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... -- Donald Spector , a renowned celebrated entrepreneur ... a Wearable Biosensor, which will issue today, September 2, ... Mr. Spector holds some of the earliest patents in ... by New York College of Health Professions, which has ... intellectual properties.  New York College noted that the Wearable ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... an overview of the company at the Morgan Stanley Global ... , Presentation date: Tuesday September 9, 2014 , ... live webcast and 30-day archive of this presentation will be ... Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:9/2/2014)... Today, Therapy Changes released ... Me?” The guide outlines common questions an individual may ... to common types of groups an individual can attend. ... the interventions of the therapist, but also from observing ... members,” says Rochelle Perper, Ph.D. and founder of Therapy ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud ... a contemporary marketing presence and visually solidifies the ... Friendship Senior Options,” said Stephen A. Yenchek, president ... the logo, we are making sure that our ... their families.” , Friendship Village is a retirement ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... cancer-prevention gene in the response to drug treatment for childhood ... known as the guardian of the genome, is known for ... gene are associated with a high incidence of cancer due ... tumours. , In childhood cancers such as neuroblastoma, p53 mutations ...
... tuning out distractions can be learned , MONDAY, Nov. ... a person,s brain is organized, says a U.S. study that ... training. , All the participants were between the ages of ... than 10 years experience as a band or orchestra director ...
... FDA says clotting drug poses increased death risk, while company ... (HealthDay News) -- Bayer AG suspended worldwide sales of Trasylol, ... on Monday following a request from the U.S. Food and ... for safety reasons. , The FDA cannot identify a patient ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... Inc. (Nasdaq: ALTH ) today reported financial results for ... 30, 2007, the,Company reported a net loss of $9.3 million, ... $8.1 million, or ($0.15) per share, for the third,quarter of ... Company,reported a net loss of $28.1 million, or ($0.43) per ...
... 5 Hooper Holmes,Inc. (AMEX: HH ) announced ... after-market on Thursday, November 8, 2007. The Company,will host ... 11:00 a.m.,Eastern Time. To participate in the third ... Hooper Holmes. A live web cast,will be hosted on ...
Cached Medicine News:Health News:Training, Experience Can Change How Brains Work 2Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 3Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 4Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 5Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 6Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 7Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: